Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Prophylactic and Therapeutic Monoclonal Antibodies, 20113 [05-7608]

Download as PDF Federal Register / Vol. 70, No. 73 / Monday, April 18, 2005 / Notices Submit comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: FAR Desk Officer, OMB, Room 10102, NEOB, Washington, DC 20503, and a copy to the General Services Administration, FAR Secretariat (VIR), 1800 F Streets, NW, Room 4035, Washington, DC 20405. ADDRESSES: Jerry Olson, Contract Policy Division, GSA (202) 501–3221. FOR FURTHER INFORMATION CONTACT: SUPPLEMENTARY INFORMATION: A. Purpose The North Carolina Sales and Use Tax Act authorizes counties and incorporated cities and towns to obtain each year from the Commissioner of Revenue of the State of North Carolina a refund of sales and use taxes indirectly paid on building materials, supplies, fixtures, and equipment that become a part of or are annexed to any building or structure in North Carolina. However, to substantiate a refund claim for sales or use taxes paid on purchases of building materials, supplies, fixtures, or equipment by a contractor, the Government must secure from the contractor certified statements setting forth the cost of the property purchased from each vendor and the amount of sales or use taxes paid. Similar certified statements by subcontractors must be obtained by the general contractor and furnished to the Government. The information is used as evidence to establish exemption from State and local taxes. B. Annual Reporting Burden Respondents: 424. Responses Per Respondent: 1. Annual Responses: 424. Hours Per Response: .17. Total Burden Hours: 72. Obtaining Copies of Proposals: Requesters may obtain a copy of the information collection documents from the General Services Administration, FAR Secretariat (VIR), Room 4035, 1800 F Street, NW, Washington, DC 20405, telephone (202) 501–4755. Please cite OMB Control No. 9000–0059, North Carolina Sales Tax Certification, in all correspondence. Dated: April 7, 2005 Julia B. Wise Director, Contract Policy Division. [FR Doc. 05–7617 Filed 4–15–05; 8:45 am] BILLING CODE 6820–EP–S VerDate jul<14>2003 16:08 Apr 15, 2005 Jkt 205001 DEPARTMENT OF DEFENSE Department of the Army Armed Forces Institute of Pathology Scientific Advisory Board Department of the Army, DoD. Notice of open meeting. AGENCY: ACTION: SUMMARY: In accordance with 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463) announcement is made of the following open meeting: Name of Committee: Scientific Advisory Board (SAB). Dates of Meeting: May 19–20, 2005. Place: The Armed Forces Institute of Pathology, 14th St. & Alaska Ave., NW., Building 54, Washington, DC 20306– 6000. Time: 8:30 a.m.–4:45 p.m. (May 19, 2005). 8 a.m.–12 p.m. (May 20, 2005). FOR FURTHER INFORMATION CONTACT: Mr. Ridgely Rabold, Office of the Principal Deputy Director (PDD), AFIP, Building 54, Washington, DC 20306–6000, phone (202) 782–2553, e-mail: rabold@afip.osd.mil. SUPPLEMENTARY INFORMATION: General function of the board: The SAB provides scientific and professional advice and guidance on programs, policies and procedures of the AFIP. Agenda: The Board will hear status reports form the AFIP Director, Principal Deputy Director, and each of the pathology sub-specialty departments, which the Board members will visit during the meeting. Open board discussions: Reports will be presented on all visited departments, The reports will consist of findings, recommended areas of further research, improvement, and suggested solutions. New trends and/or technologies will be discussed and goals established. The meeting is open to the public. Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 05–7609 Filed 4–15–05; 8:45 am] BILLING CODE 3710–08–M DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Prophylactic and Therapeutic Monoclonal Antibodies Department of the Army, DoD. Notice. AGENCY: ACTION: SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made PO 00000 Frm 00013 Fmt 4703 Sfmt 4703 20113 of the availability for licensing of U.S. Patent Application No. 10/987,533 entitled ‘‘Prophylactic and Therapeutic Monoclonal Antibodies,’’ filed November 12, 2004. Foreign rights are also available (PCT/US04/38480). The United States Government, as represented by the Secretary of the Army, has rights in this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA–J, 504 Scott Street, Fort Detrick, Frederick, MD 21702–5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619–6664, both at telefax (301) 619–5034. SUPPLEMENTARY INFORMATION: In this application are described monoclonal antibodies which specifically recognize V antigen of Y pestis and epitopes recognized by these monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of plague infections in vitro and in vivo. Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 05–7608 Filed 4–15–05; 8:45 am] BILLING CODE 3710–08–M DEPARTMENT OF DEFENSE Department of the Army; Corps of Engineers Intent To Prepare a Draft Programmatic Environmental Impact Statement for Community Relocation, Newtok, AK Department of the Army, U.S. Army Corps of Engineers, DoD. ACTION: Notice of intent. AGENCY: SUMMARY: The U.S. Army Engineer District, Alaska, intends to prepare a Draft Programmatic Environmental Impact Statement (DEIS) to evaluate the feasibility of erosion protection measures for the community of Newtok, Alaska. Newtok, population 284 (2000 census), is a coastal community situated on the west bank of the Newtok River, just north of the Ninglick River and approximately 9 miles northwest of Nelson island, The Ninglick River connects the Bering Sea with the Baird Inlet, located farther upstream from Newtok. The village is located 94 miles E:\FR\FM\18APN1.SGM 18APN1

Agencies

[Federal Register Volume 70, Number 73 (Monday, April 18, 2005)]
[Notices]
[Page 20113]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-7608]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Application Concerning Prophylactic and 
Therapeutic Monoclonal Antibodies

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is 
made of the availability for licensing of U.S. Patent Application No. 
10/987,533 entitled ``Prophylactic and Therapeutic Monoclonal 
Antibodies,'' filed November 12, 2004. Foreign rights are also 
available (PCT/US04/38480). The United States Government, as 
represented by the Secretary of the Army, has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA-J, 504 Scott Street, Fort 
Detrick, Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664, both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: In this application are described monoclonal 
antibodies which specifically recognize V antigen of Y pestis and 
epitopes recognized by these monoclonal antibodies. Also provided are 
mixtures of antibodies of the present invention, as well as methods of 
using individual antibodies or mixtures thereof for the detection, 
prevention, and/or therapeutical treatment of plague infections in 
vitro and in vivo.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 05-7608 Filed 4-15-05; 8:45 am]
BILLING CODE 3710-08-M